Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms
Top Cited Papers
- 10 January 2025
- journal article
- review article
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 21 (4) , 193-203
Abstract
Three monoclonal antibodies directed against specific forms of the amyloid-β (Aβ) peptide have been granted accelerated or traditional approval by the FDA as treatments for Alzheimer disease, representing the first step towards bringing disease-modifying treatments for this disease into clinical practice. Here, we review the detection, underlying pathophysiological mechanisms and clinical implications of amyloid-related imaging abnormalities (ARIA), the most impactful adverse effect of anti-Aβ immunotherapy. ARIA appears as regions of oedema or effusions (ARIA-E) in brain parenchyma or sulci or as haemorrhagic lesions (ARIA-H) in the form of cerebral microbleeds, convexity subarachnoid haemorrhage, cortical superficial siderosis or intracerebral haemorrhage. Analysis of the radiographic appearance of ARIA, its clinical risk factors and underlying neuropathology, and results from animal models point to a central role for cerebral amyloid angiopathy — a condition characterized by cerebrovascular Aβ deposits — as a key component, either as a direct target for antibody-mediated inflammation or as recipient of Aβ mobilized from plaques in the Alzheimer brain parenchyma. The great majority of ARIA occurrences are associated with mild or no clinical symptoms. However, ~5% of all ARIA events are severe enough to result in hospitalization, permanent disability or death and thus raise challenging clinical questions regarding patient selection and use of concomitant agents. Therefore, identifying novel approaches to predicting, modelling, preventing and treating ARIA remains a key step towards allowing safe use of anti-Aβ immunotherapy for the world’s rapidly ageing population.Keywords
This publication has 88 references indexed in Scilit:
- MR Imaging Detection of Cerebral Microbleeds: Effect of Susceptibility-Weighted Imaging, Section Thickness, and Field StrengthAmerican Journal of Neuroradiology, 2008
- Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brainBrain, 2008
- Immunotherapy Reduces Vascular Amyloid- in PDAPP MiceJournal of Neuroscience, 2008
- Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid βThe Journal of Neuroscience, 2005
- Clinical manifestations of cerebral amyloid angiopathy–related inflammationAnnals of Neurology, 2004
- Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhageJournal of Neuroinflammation, 2004
- Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's DiseaseBrain Pathology, 2004
- Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunizationNeurology, 2003
- Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case reportNature Medicine, 2003
- Cerebral Hemorrhage After Passive Anti-Aβ ImmunotherapyScience, 2002